irinotecan has been researched along with acrylonitrile in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiyama, R; Asakawa, N; Furuta, T; Hatano, H; Igarashi, Y; Kodaira, H; Matsuzaki, T; Nishiyama, Y; Sugimoto, Y; Takahashi, H; Yagi, N; Yamazaki, R | 1 |
| Matsuzaki, T; Nagaoka, M; Shishido, Y; Ueno, S; Yamazaki, R | 1 |
2 other study(ies) available for irinotecan and acrylonitrile
| Article | Year |
|---|---|
Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Topics: Acrylonitrile; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Proteins; Neoplasms; Xenograft Model Antitumor Assays | 2011 |
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Topics: Acrylonitrile; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Side-Population Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |